Edition:
United States

Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

41.68USD
26 May 2017
Change (% chg)

$-0.18 (-0.43%)
Prev Close
$41.86
Open
$41.78
Day's High
$41.85
Day's Low
$41.51
Volume
271,105
Avg. Vol
508,101
52-wk High
$57.42
52-wk Low
$30.90

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 0.67
Market Cap(Mil.): $81,489.81
Shares Outstanding(Mil.): 1,962.56
Dividend: 0.67
Yield (%): 3.22

Financials

  NVO.N Industry Sector
P/E (TTM): 18.06 14.27 17.41
EPS (TTM): 2.30 -- --
ROI: 89.20 -7.17 -5.42
ROE: 99.57 -6.63 -4.68

Novo Nordisk looks to expand Latin American obesity business

COPENHAGEN Danish drugmaker Novo Nordisk is looking to expand its obesity business in Latin America on the back of "phenomenal" performance by its new anti-obesity injection Saxenda, a senior company official said on Monday.

May 22 2017

Novo Nordisk looks to expand Latin American obesity business

COPENHAGEN, May 22 Danish drugmaker Novo Nordisk is looking to expand its obesity business in Latin America on the back of "phenomenal" performance by its new anti-obesity injection Saxenda, a senior company official said on Monday.

May 22 2017

Novelion CEO quits Novo Nordisk board due to NASH conflict

Danish drugmaker Novo Nordisk said on Tuesday the chief executive of Canadian biotech company Novelion Therapeutics had left its board with immediate effect due to "a potential conflict of interest".

May 16 2017

Novelion CEO quits Novo Nordisk board due to NASH conflict

May 16 Danish drugmaker Novo Nordisk said on Tuesday the chief executive of Canadian biotech company Novelion Therapeutics had left its board with immediate effect due to "a potential conflict of interest".

May 16 2017

BRIEF-Novo Nordisk: Novelion CEO leaves board to avoid potential conflict of interest

* Says Mary Szela steps down from Novo Nordisk's board of directors with immediate effect

May 16 2017

Novo Nordisk bets on new obesity drug recipes

LONDON Hit by pricing pressure in its core insulin business, Danish drugmaker Novo Nordisk is looking at new treatments for obesity - a major cause of diabetes - to help revive its growth.

May 11 2017

BRIEF-Novo Nordisk renews agreement with NNIT

* SAID ON THURSDAY ENTERED INTO A 6-YEAR-AGREEMENT WITH NOVO NORDISK, REPLACING AN EXISTING CORPORATE CORE IT INFRASTRUCTURE OUTSOURCING CONTRACT

May 05 2017

BRIEF-Novo Nordisk launches Xultophy® 100/3.6 (insulin degludec and liraglutide injection) in U.S.

* Launches Xultophy® 100/3.6 (insulin degludec and liraglutide injection) in United States Source text for Eikon: Further company coverage:

May 03 2017

Danish drugmaker Novo Nordisk nudges up forecasts after first-quarter result

COPENHAGEN Shares in Novo Nordisk , the world's biggest maker of diabetes drugs, surged on Wednesday as the Danish firm beat operating profit forecasts for the first quarter and nudged up its full-year target.

May 03 2017

UPDATE 2-Danish drugmaker Novo Nordisk nudges up forecasts after Q1 result

* Novo's share price up 6 pct (Adds detail on peers, outlook for pricing pressure, analyst, updates share price)

May 03 2017

More From Around the Web

Competitors

  Price Chg
Sanofi SA (SASY.PA) €87.74 +0.43
Eli Lilly and Co (LLY.N) $78.05 -0.29

Earnings vs. Estimates